Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis.

Martin J BergmanAlan J KivitzDimitrios A PappasJoel M KremerLixia ZhangAnna JeterJohanna B Withers

Published in: Rheumatology and therapy (2020)

If PrismRA is implemented into routine clinical care as modeled, predicting which RA patients will have an inadequate response to anti-TNF therapies could save > $7 million in overall ineffective healthcare costs per 1000 patients tested and increase targeted DMARD response rates in RA.

Keyphrases

rheumatoid arthritis
healthcare
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
systemic lupus erythematosus
patient reported outcomes
cancer therapy
chronic pain